Kyung Dong Pharmaceutical Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Deok-Hee Ryu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 1.4% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05CEO
Deok-Hee Ryu (86 yo)
no data
Tenure
Deok-Hi Ryu serves as the Chief Executive Officer, President and Chairman for Kyungdong Pharm Co. Deok-Hi Ryu serves as President of Korea Pharmaceutical Industry Cooperation. Deok-Hi Ryu serves as Vice Ch...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:55 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyung Dong Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hong-Sik Jeong | LS Securities Co., Ltd. |
| Tae Gi Ha | SK Securities Co., Ltd. |